Skip to Content

Ribavirin Teva

Active Substance: ribavirin
Common Name: ribavirin
ATC Code: J05AB04
Marketing Authorisation Holder: Teva B.V.
Active Substance: ribavirin
Status: Authorised
Authorisation Date: 2009-03-31
Therapeutic Area: Hepatitis C, Chronic
Pharmacotherapeutic Group: Antivirals for systemic use

Therapeutic Indication

Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used. 

There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b).

Naïve patients 

Adult patients 

Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA. 

Paediatric patients (children 3 years of age and older and adolescents) 

Ribavirin Teva is indicated, in a combination regimen with interferon alfa­2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.

When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis. 

Previous treatment failure patients

Adult patients 

Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.

What is Ribavirin Teva?

Ribavirin Teva is a medicine that contains the active substance ribavirin. It is available as white capsules (200 mg).

Ribavirin Teva is a ‘generic medicine’. This means that it is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Rebetol.

What is Ribavirin Teva used for?

Ribavirin Teva is used to treat patients aged three years and older who have chronic (long-term) hepatitis C (a disease of the liver due to an infection with the hepatitis-C virus). Ribavirin Teva must never be used on its own but only together with interferon alfa‑2b (another medicine used in hepatitis).

Ribavirin Teva can be used in ‘naïve’ patients (who have not been treated before) for all types of hepatitis C except for genotype 1. It can also be used in adults who previously responded to treatment with interferon alfa but whose disease has come back.

The medicine can only be obtained with a prescription.

How is Ribavirin Teva used?

Treatment with Ribavirin Teva should be started and monitored by a doctor who has experience in the management of chronic hepatitis C.

The dose of Ribavirin Teva is based on the patient’s body weight, and ranges from three to seven capsules a day. It should only be taken by patients weighing at least 47 kg. Ribavirin Teva is taken with food each day in two divided doses (morning and evening). The duration of treatment depends on the patient’s condition and response to treatment, and ranges from 24 weeks to a year. The dose may need to be adjusted for patients who experience side effects. For more information, see the package leaflet.

How does Ribavirin Teva work?

The active substance in Ribavirin Teva, ribavirin, is an antiviral belonging to the class ‘nucleoside analogues’. Ribavirin Teva is thought to interfere with the production or action of viral DNA and RNA, which are needed for viruses to survive and multiply. Ribavirin Teva on its own has no effect on eliminating the hepatitis-C virus from the body.

How has Ribavirin Teva been studied?

Because Ribavirin Teva is a generic medicine, studies have been limited to tests to demonstrate that it is bioequivalent to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the benefit and risk of Ribavirin Teva?

Because Ribavirin Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.

Why has Ribavirin Teva been approved?

The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Ribavirin Teva has been shown to have comparable quality and to be bioequivalent to Rebetol. Therefore, the CHMP’s view was that, as for Rebetol, the benefit outweighs the identified risk. The Committee recommended that Ribavirin Teva be given marketing authorisation.

Other information about Ribavirin Teva

The European Commission granted a marketing authorisation valid throughout the EU for Ribavirin Teva to Teva Pharma B.V. on 31 March 2009.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.